{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:20:32Z","timestamp":1768587632660,"version":"3.49.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Endocrinology & Metabolism"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1586\/eem.10.83","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T14:19:10Z","timestamp":1292595550000},"page":"21-30","source":"Crossref","is-referenced-by-count":4,"title":["Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy"],"prefix":"10.1586","volume":"6","author":[{"given":"Maria Gracia","family":"Mateo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Mar","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tips.2004.12.005","volume":"26","author":"Villarroya","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00005"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183629.20041.bb"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"CIT0006","first-page":"L63","volume":"8","author":"Milinkovic","year":"2003","journal-title":"Antivir. Ther."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2009.06.011","volume":"208","author":"Guaraldi","year":"2010","journal-title":"Atherosclerosis"},{"key":"CIT0009","unstructured":"Guaraldi G, Zona S, Orlando Get al.Visceral fat but not general adiposy is a predictor of cardiovascular disease in HIV-infected males. Presented at:17thConference on Retroviruses and Opportunistic Infection.San Francisco, CA, USA, 16\u201319 February 2010."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ajcn\/61.6.1290","volume":"61","author":"Snel","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"CIT0011","first-page":"580","volume":"20","author":"De Boer","year":"1996","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"CIT0012","first-page":"504","volume":"86","author":"Rietschel","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1152\/ajpendo.00335.2003","volume":"286","author":"Koutkia","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-199912030-00023","volume":"13","author":"Torres","year":"1999","journal-title":"AIDS"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-199910220-00013","volume":"13","author":"Wanke","year":"1999","journal-title":"AIDS"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7785"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00042560-200208010-00002","volume":"30","author":"Engelson","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8391"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jnci\/91.7.620","volume":"91","author":"Ma","year":"1999","journal-title":"J. Natl Cancer Inst."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.210"},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/j.1550-8528.1996.tb00511.x","volume":"4","author":"L\u00f6nn","year":"1996","journal-title":"Obes. Res."},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000180099.35146.30"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072375"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830a5058"},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","volume":"53","author":"Falutz","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1172\/JCI112679","volume":"78","author":"Frohman","year":"1986","journal-title":"J. Clin. Invest."},{"key":"CIT0029","unstructured":"Larocque A, Vaillancourt C, Abribat Tet al.Anchoring rigid hydrophobic chains to stabilize growth hormone-releasing factor. Theratechnologies Inc., St. Laurent and University of Montreal, Montreal, Quebec, Canada (2001)."},{"key":"CIT0030","unstructured":"Michaud S-E, Abolfathi Z. Pharmacokinetic\/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations. Presented at:Endocrine Society\u2019s 91st Annual Meeting. Washington, DC, USA, 10\u201313 June 2009."},{"key":"CIT0031","unstructured":"Falutz J, Mamputu J-C. Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in hiv-infected patients with excess abdominal fat over a period of 52 weeks. a pooled analysis of 2 multicenter, double- blind, placebo-controlled Phase 3 trials with 816 randomized patients. Presented at:12th European AIDS Conference. Cologne, Germany, 11\u201314 November 2009."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2007.00008.x"},{"key":"CIT0033","unstructured":"Vincent G, Teng S. Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers. Presented at:18th Annual Canadian Conference on HIV\/AIDS Research.Vancouver, BC, Canada, 23\u201326 April 2009."}],"container-title":["Expert Review of Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/eem.10.83","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T05:16:09Z","timestamp":1559884569000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/eem.10.83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1586\/eem.10.83"],"URL":"https:\/\/doi.org\/10.1586\/eem.10.83","relation":{},"ISSN":["1744-6651","1744-8417"],"issn-type":[{"value":"1744-6651","type":"print"},{"value":"1744-8417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}